Method for the prognosis and treatment of cancer metastasis
US10866241B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 30, 2017 |
| Grant date | Dec 15, 2020 |
| Priority date | — |
| Expiry date | May 30, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4706
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.